Dexamethasone prevents visceral hyperalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats

Gut

Volumn 56, Issue 8, 2007, Pages 1072-1078

  Róka, Richard ^a   Ait Belgnaoui, Afifa ^a   Salvador Cartier, Christel ^a   Garcia Villar, Raphael ^a   Fioramonti, Jean ^a   Eutamène, Hélène ^a   Bueno, Lionel ^a  

^a CEMAGREF   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXANTRAZOLE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROMYOGRAPHY; ENZYME ACTIVATION; EXPERIMENTAL MODEL; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CELL COUNT; COLON; DEXAMETHASONE; GLUCOCORTICOIDS; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; INFUSIONS, PARENTERAL; INJECTIONS, INTRAPERITONEAL; INTESTINAL MUCOSA; MALE; MAST CELLS; METALLOENDOPEPTIDASES; OLIGOPEPTIDES; PERMEABILITY; RATS; RATS, WISTAR; RECEPTOR, PAR-2; THIOXANTHENES; VISCERA; XANTHONES;

EID: 34547165906     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.115352     Document Type: Article

References (45)

1. Barbara G, De Giorgio R, Stanghellini V, et al. New pathophysiological mechanisms in irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1-9.
2. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal endocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000;47:804-11.
3. Dunlop SP, Jenkins D, Nela KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-9.
4. Dunlop SP, Jenkins D, Neal KR, et al. Randomized, double-bind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:77-84.
5. 5 Nystedt S, Lanson AK, Aberg H, et al. The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression. J Biol Chem 1995;270:5950-5.
6. Coelho AM, Vergnolle N, Guiard B, et al. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 2002;122:1035-47.
7. Kawao N, Ikeda H, Kitano T, et al. Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J Pharmacol Sci 2004;94:277-85.
8. Reed DE, Barajas-Lopez C, Cottrell G, et al. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. J Physiol 2003;547:531-42.
9. Roka R, Rosztoczy A, Leveque M, et al. Fecal serine-protease activity: a patholological factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007 (Epub ahead of print.).
10. Gecse K, Roka R, Rosztoczy A, et al. Fecal serine-protease activity: a pathophysiological factor and a possible diagnostic marker for diarrhoea-predominant irritable bowel syndrome [abstract]. Gut, 2006;57(Suppl I):A67.
11. Morteau O, Hachet T, Causette M, et al. Experimental colitis alters visceromotor response to colorectal distension in awake rats. Dig Dis Sci 1994;39:1239-48.
12. Isgar B, Herman M, Kaye MD, et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 1983;24:190-2.
13. Gwee KA, Graham JC, McKendrick MW, et al. Psychometris scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996;347:150-3.
14. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of irritable bowel syndrome: postal survey of patients. BMJ 1997;314:779-82.
15. Bercik P, Wang L, Verdu EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 2004;127:179-87.
16. Huerta C, Garcia Rodriguez LA, Wallander MA, et al. Users of oral steroids are at a reduced risk of developing irritable bowel syndrome. Pharmacoepidemiol Drug Saf 2003;12:583-8.
17. Huerta C, Garcia Rodriguez LA, Wallander MA, et al. Risk of irritable bowel syndrome among asthma patients. Pharmacoepidemiol Drug Saf 2002;11:31-5.
18. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cell in the irritable bowel syndrome. Neurogastroenterol Mot 2000;12:449-57.
19. Park CH, Joo YE, Choi SK, et al. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J Korean Med Sci 2003;18:204-10.
20. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523-6.
21. Barbara G, Stanghellini V, DiGiorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
22. King SJ, Miller HRP, Newlands GFJ, et al. Depletion of mucosal mast cell protease by corticosteroids: effect on intestinal anaphylaxis in the rat. Proc Natl Acad Sci USA 1985;82:1214-8.
23. Goldsmith P, McGarity B, Walls AF, et al. Corticosteroid treatment reduces mast cell number in inflammatory bowel disease. Dig Dis Sci 1990;35:1409-13.
24. Zhao Y, Leung PC, Woo KS, et al. Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1). Inflamm Res 2004;53:664-9.
25. Cohan VL, Undem BJ, Fox CC, et al. Dexamethasone dose not inhibit the release of mediators from human mast cell residing in airway, intestine, or skin. Rev Respir Dis 1989;140:951-4.
26. Bohm SK, Kong W, Bromme D, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 1996;314:1009-16.
27. Kunzelmann K, Schreiber R, Konig J, et al. Ion transport induced by proteinase-activated receptors (PAR2) in colon and airways. Cell Biochem Biophys 2002;36:209-14.
28. Cenac N, Coelho AM, Nguyen C, et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 2002;161:1903-15.
29. Cenac N, Garcia-Villar R, Ferrier L, et al. Proteinase-activated receptor-2-induced colonic inflammation in mice: possible involvement of afferent neurons, nitric oxide, and paracellular permeability. J Immunol 2003;170:4296-300.
30. Cenac N, Chin AC, Garcia-Villar R, et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-γ dependent and -independent pathways. J Physiol 2004;58:913-25.
31. Ait-Belgnaoui A, Gradesi S, Fioramonti J, et al. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005;113:141-7.
32. Santos J, Yang PC, Soderholm JD, et al. Role of mast cells in chronic stress induced colonic epithelial barrier dysfunction in the rat. Gut 2001;48:630-6.
33. Moriez R, Salvador-Cartier C, et al. Myosin light chain kinase is involved in lipopolysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol 2005;167:1071-9.
34. Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004;20:1317-22.
35. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94.
36. Jacob C, Yang PC, Darmoul D, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J Biol Chem, 280:31936-48.
37. Roka R, Demaude J, Cenac N, et al. Colonic luminal proteases activate colonocyte proteinase-activated receptor-2 and regulate paracellular permeability in mice. Neurogastroenterol Motil 2007;19:57-65.
38. O'Sullivan M, Clayton N, Breslin NP, et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000;12:449-57.
39. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
40. Park JH, Rhee PL, Kim HS, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006;21:71-8.
41. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003;98:1578-83.
42. Tremaine WJ, Brzezinski A, Katz JA, et al. Treatment of mildly to moderate active ulcerative colitis with tryptase inhibitor (APC 2059): an open labelled pilot study. Aliment Pharmacol Ther 2002;16:407-13.
43. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazyne and 5-amonisalicylic acid. Dig Dis Sci 1991;36:179-84.
44. Serna H, Porras M, Vergara P. Mast cell stabilizer Ketotifen prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental T. spiralis inflammation in the rat. J Pharmacol Exp Ther 2006;319:1104-11.
45. Grazioli I, Melzi G, Balsamo V, et al. Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet. Minerva Pediatr 1993;45:253-8.